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Regional haemodynamic responses to adenosine
receptor activation vary across time following
lipopolysaccharide treatment in conscious rats
L Jolly, JE March, PA Kemp, T Bennett and SM Gardiner
Centre for Integrated Systems Biology and Medicine, School of Biomedical Sciences, Queens Medical Centre, University of Nottingham
Medical School, Nottingham, UK
Background and purpose: Studies using adenosine receptor antagonists have shown that adenosine-mediated vasodilatations
play an important role in the maintenance of regional perfusion during sepsis, but it is unclear whether vascular sensitivity to
adenosine is affected. Here, we assessed regional haemodynamic responses to adenosine agonists and antagonists in normal
and lipopolysaccharide (LPS)-treated rats to investigate a possible role for adenosine in the haemodynamic sequelae.
Experimental approach: Male Sprague–Dawley rats were chronically instrumented with pulsed Doppler flow probes to
measure regional haemodynamic responses to adenosine-receptor agonists (adenosine, 2-choloro-N
6-cyclopentyladenosine
(CCPA)) and antagonists (8-phenyltheophylline (8-PT), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX)), at selected time points
in control and LPS-treated rats.
Key results: The responses to 8-PT were consistent with endogenous adenosine causing bradycardia, and renal and
hindquarters vasodilatation in control rats, whereas in LPS-treated rats, there was evidence for endogenous adenosine causing
renal (at 1.5h) and hindquarters (at 6h) vasoconstriction. In control animals, exogenous adenosine caused hypotension,
tachycardia and widespread vasodilatation, whereas in LPS-treated rats, the adenosine-induced renal (at 1.5h) and
hindquarters (at 6h) vasodilatations were abolished. As enhanced A1 receptor-mediated vasoconstriction could explain the
results in LPS-treated rats, vascular responsiveness to a selective A1-receptor agonist (CCPA) or antagonist (DPCPX) was
assessed. There was no evidence for enhanced vasoconstrictor responsiveness to CCPA in LPS-treated rats, but DPCPX caused
renal vasodilatation, consistent with endogenous adenosine mediating renal vasoconstriction under these conditions.
Conclusions and implications: The results show changes in adenosine receptor-mediated cardiovascular effects in
endotoxaemia that may have implications for the use of adenosine-based therapies in sepsis.
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Introduction
The cardiovascular sequelae of sepsis include a hyperdy-
namic phase that progresses into a hypodynamic stage as
the severity of the condition increases. During the hyper-
dynamic phase, patients may remain normotensive, despite
systemic vasodilatation, due to an increase in cardiac output.
A role for adenosine in the haemodynamic changes
associated with sepsis during this early stage has been
postulated by a number of researchers (Martin et al., 2000;
Law et al., 2003; Conlon et al., 2005).
Adenosine has a short biological half-life making it an
unlikely circulating mediator, but may act locally to cause
regionally selective changes in vascular tone (Berne, 1986).
There are four subtypes of G-protein-coupled adenosine
receptor (A1,A 2a,A 2b and A3) (Fredholm et al., 2001b), and
evidence suggests that A1 and A2 receptors are primarily
responsible for the cardiovascular actions of adenosine
(Fredholm et al., 2001a). A1 receptors are linked to Gi causing
inhibition of cAMP activity, which leads to cardiac depres-
sion, a reduction in heart rate and renal vasoconstriction
(Evans et al., 1982; Webb et al., 1990; Fredholm et al., 2001a;
Hansen et al., 2005). However, evidence also suggests that A1
receptors are involved in vasodilatation in skeletal muscle
through effects on KATP channels, prostaglandin and nitric
oxide production (Marshall et al., 1993; Ray et al., 2002; Ray
BJPOpen
Received 18 March 2008; revised 22 April 2008; accepted 23 April 2008;
published online 26 May 2008
Correspondence: Professor SM Gardiner, Centre for Integrated Systems
Biology and Medicine, School of Biomedical Sciences, Queen’s Medical
Centre, University of Nottingham, Nottinghamshire NG7 2UH, UK.
E-mail: sheila.gardiner@nottingham.ac.uk
British Journal of Pharmacology (2008) 154, 1600–1610
& 2008 Nature Publishing Group All rights reserved 0007–1188/08 $30.00
www.brjpharmacol.organd Marshall, 2006). A2a receptors are located on vascular
smooth muscle, endothelial cells and on immune cells, and
are linked to Gs, leading to cAMP activation (Mubagwa
et al., 1996; Fredholm et al., 2001a; Nemeth et al., 2006).
A2a-receptor-mediated effects of adenosine include vasodila-
tation and immunosuppression (Webb et al., 1990; Nemeth
et al., 2006). A2b receptor activation may also lead to
regionally selective vasodilatation, but the lack of pharma-
cological probes selective for A2b receptors means this
subtype is poorly characterized (Feoktistov and Biaggioni,
1997.
Endogenous adenosine has been shown to contribute to
changes in regional blood flow distribution during sepsis,
thereby promoting the development of a hyperdynamic
circulation. For example, Motew et al. (1998) showed that,
24h after a septic challenge, the non-selective adenosine
receptor antagonist, 8-phenyltheophylline (8-PT), caused
vasoconstriction (selective for skeletal muscle, hepatic portal
and cerebral circulations), indicating endogenous adenosine-
mediated vasodilator tone (Motew et al., 1998). However, in
that study, the animals were not vasodilated at the time of
antagonist administration and the antagonist responses were
only considered at one time point (that is, 24h) following
the septic challenge.
To extend these observations, the aim of the present study
was to determine the effects of adenosine receptor agonism
and antagonism at different times in a model of endo-
toxaemia (lipopolysaccharide (LPS) administration) in which
regionally selective vasodilatation occurs, the pattern of
which changes across time. We hypothesized that adenosine
receptor antagonism would cause vasoconstriction in re-
gions where endogenous adenosine was acting as a vaso-
dilator. However, the results of the first experiments,
contrary to expectation, were consistent with upregulation
of A1-receptor-mediated vasoconstrictor effects following
LPS administration. Therefore, further experiments were
performed to assess the haemodynamic responses to A1
receptor activation and antagonism. It is well known that A1
receptor activation causes inhibition of renin release (Tagawa
and Vander, 1970; Churchill and Churchill, 1985; Weihprecht
et al., 1990), and as there was a vasoconstrictor effect of A1
receptor antagonism in the control rats (see Results), a final
set of experiments was performed in the presence of
the angiotensin (AT1) receptor antagonist, losartan, to assess
if the vasoconstrictor effects of A1 receptor antagonism were
secondary to activation of the renin–angiotensin system.
Collectively, the experiments provide evidence for changes
in adenosine receptor-mediated cardiovascular effects in
endotoxaemia, some of which can be explained by increased
involvement of A1 receptors and some of which may be due
to a change in A2-receptor-mediated effects. Some of this
work has been presented to the British Pharmacological
Society (Jolly et al., 2008a,b).
Materials and methods
Animals and surgery
All animal procedures were carried out with the approval of
the University of Nottingham Ethical Review Committee
and were performed in accordance with Home Office
Licensing regulations. All experiments were performed in
male Sprague–Dawley rats, weighing 400–500g, supplied by
Charles River (Kent, UK). Unrestrained animals were housed
in groups of up to four prior to surgery, and individually
afterwards, with free access to food and water throughout.
Animals were kept in temperature-controlled (21–231C)
holding areas, with a 12h light–dark cycle (0600–1800
hours), in the Biomedical Services Unit at the University of
Nottingham.
All surgeries were carried out under general anaesthesia
using fentanyl citrate and medetomidine (300mgkg
 1 of
each i.p). Anaesthesia was reversed by atipamezole hydro-
chloride (1mgkg
 1 s.c.) and buprenorphine (0.3mgkg
 1
s.c.); buprenorphine also had analgesic effect. Following
surgery for probe implantation, a single injection of
amoxicillin trihydrate (150mgkg
 1 i.m.) was given. An
adequate depth of anaesthesia was determined by the
absence of an interdigit toe pinch.
At the first surgical stage, Doppler flow probes (to measure
renal, mesenteric and hindquarters blood flows) were
implanted as outlined in detail elsewhere (Gardiner et al.,
1995). Briefly, a ventral midline abdominal incision was
made, intestines were retracted and target vessels were
isolated by blunt dissection. Miniature, pulsed Doppler flow
probes were sutured around the left renal artery, the superior
mesenteric artery and the distal abdominal aorta below the
level of the ileocaecal artery (for hindquarters). Probe wires
were taken through the body wall, exiting on the left side,
with excess wires being placed in a s.c. pouch; the ends of the
wires were tunnelled s.c. to exit at a single point at the nape
of the neck. At least 10 days after probe implantation,
catheters were inserted in the right jugular vein (up to three
catheters) and the peritoneal cavity for substance adminis-
tration, and in the distal aorta (via the caudal artery), for
continuous recording of arterial BP and heart rate. All
catheters were tunnelled s.c. to exit the body, along with
the probe wires, via a single incision at the back of the neck.
The arterial catheter was connected to a fluid-filled swivel
overnight, through which heparinized saline (15UmL
 1;
0.4mLh
 1) was infused to maintain catheter patency.
Experiments began at least 24h after catheter implantation,
in unrestrained, conscious animals.
Cardiovascular measurements
BP was measured via a fluid-filled arterial catheter connected
to a pressure transducer (Gould, Cleveland, OH, USA; type
4-442) and transducer amplifier (Gould; model 13-4615-50),
which interfaced with a custom-designed haemodynamics
data acquisition system (built by the Bioinstrumentation
Laboratories at the University of Maastricht, The Netherlands).
The signals from the Doppler flow probes also interfaced
with the haemodynamics data acquisition system via a
Doppler flow meter (Crystal Biotech, Holliston, MA, USA)
VF-1 mainframe fitted with high-velocity (HVPD-20)
modules. The signals were sampled by haemodynamics data
acquisition system every 2ms, averaged every cardiac cycle
and stored to disc at 5-s intervals for later analysis, using
custom-designed software (Datview; University of Limburg,
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cardiovascular responses over selected intervals.
Experimental protocols
Experiment 1: cardiovascular effects of 8-PT in normal and
LPS-treated rats. Responses to the non-selective adenosine
receptor antagonist, 8-PT (4mgkg
 1 in saline given as a
0.1mL bolus), were assessed 1.5, 6 and 25h after bolus
administration of saline (0.5mL i.p.) (n¼9), or LPS
(1mgkg
 1 i.p.) (n¼9) to determine whether endogenous
adenosine affected resting vascular tone in normal or
endotoxaemic animals, and whether any effects of 8-PT
changed across time. This antagonist shows equal selectivity
for A1 and A2 receptors (Fredholm et al., 1987), and the dose
was that used by Motew et al. (1998). In our pilot
experiments, it was shown to fully antagonize the cardio-
vascular effects of adenosine (300mgkg
 1min
 1 i.v.) for up to
60min. These pilot experiments also indicated that adeno-
sine-mediated responses had returned to normal within 6h
following 8-PT administration.
Experiment 2: cardiovascular responses to adenosine in normal
and LPS-treated rats. To determine whether the vascular
sensitivity to adenosine was altered following LPS treatment,
cardiovascular changes during 3-min infusions of adenosine
(300mgkg
 1min
 1 i.v. in saline (0.15mLmin
 1) were as-
sessed 1.5, 6 and 25h following bolus administration of
saline (0.5mL i.p.) on day 1 and following LPS (1mgkg
 1
i.p.) on day 3 (n¼9). The dose of adenosine was chosen on
the basis of pilot studies that showed it to cause robust and
reproducible vasodilatations in normal animals.
As the responses to 8-PT and adenosine had returned to
baseline 25h after administration of LPS (see Results), the
following experiments were performed only at 1.5 and 6h.
Experiment 3: cardiovascular responses to 2-choloro-N
6-cyclo-
pentyladenosine. Haemodynamic responses during 3-min
infusions of the A1 receptor agonist, 2-choloro-N
6-cyclo-
pentyladenosine (CCPA) (1.4mgkg
 1min
 1 i.v .(0.15mLmin
 1
in vehicle containing 5% propylene glycol, 2% Tween-80 in
saline)) were assessed in one group of animals (n¼8) at 1.5h
after saline (0.5mL i.p.) on day 1 and 1.5h after LPS
(1mgkg
 1 i.p.) on day 3, and in another group of animals
(n¼8) at 6h after saline (as above) on day 1 and 6h after
LPS (as above) on day 3. Results from pilot studies (L Jolly,
unpublished observations) showed that, at the dose used,
CCPA caused reproducible changes in regional vascular
conductances, which were consistent with A1 receptor
activation as reported in the literature. Different animals
were used at the two time points because of desensitization
to this agonist (Casati et al., 1994).
Experiment 4: cardiovascular effects of 8-cyclopentyl-1,3-dipropyl-
xanthine in normal and LPS-treated rats. Responses to the A1
receptor antagonist, 8-cyclopentyl-1,3-dipropylxanthine
(DPCPX) (0.1mgkg
 1 in 0.1mL of vehicle containing 5%
propylene glycol, 2% Tween-80 in saline), were assessed at
1.5 and 6h following saline (0.5mL i.p.) on day 1 and at 1.5
and 6h after LPS (1mgkg
 1 i.p.) on day 3 (n¼8). The dose
and method of delivery of DPCPX were chosen on the basis
of the literature showing successful administration of the
antagonist in vivo (Kellett et al., 1989; Bryan and Marshall,
1999), and on pilot studies conducted prior to beginning
these experiments (L Jolly, unpublished observations). Diffi-
culty in dissolving the antagonist limited its use as an infusion,
but at the dose given we were able to completely antagonize
the effects of CCPA, and the antagonism had reversed by 6h
(L Jolly, unpublished observations); this time course of action is
consistent with the literature (Kellett et al., 1989).
Experiment 5: cardiovascular effects of DPCPX following
pretreatment with losartan. Antagonism of A1 receptors can
cause renin release, and hence any cardiovascular effect
could be secondary to activation of the renin–angiotensin
system (Tagawa and Vander, 1970; Jackson, 1991). To assess
whether the regional haemodynamic responses to DPCPX
were due to direct A1 receptor antagonism or due to renin–
angiotensin system activation, the effects of DPCPX were
measured in the presence of the angiotensin (AT1) receptor
antagonist losartan (10mgkg
 1 in distilled water given as a
0.1mL i.v. bolus). Losartan was given 30min prior to
i.p. administration of saline or LPS (as above) and DPCPX
(0.1mgkg
 1 as above) was given 1.5 and 6h later. In pilot
experiments, it became clear that the marked effects of
losartan on baseline haemodynamic status in LPS-treated
rats confounded interpretation of results using DPCPX and
therefore, only results from control animals are presented.
Data analysis. As the data could not all be considered to be
normally distributed, non-parametric statistical tests were
used. Within-group analysis of data was performed using
Friedman’s test (non-parametric version of ANOVA), with
Po0.05 taken as significant. Between-group analysis was
performed using the Wilcoxon test for comparison of paired
sets of data, the Mann–Whitney U test for comparison of
unpaired data sets, and the Kruskall–Wallis test for compar-
isons between multiple unpaired data sets.
Drugs
Fentanyl citrate (Sublimaze) was from Janssen-Cilag (High
Wycombe, UK); medetomidine hydrochloride (Domitor)
and atipamezole hydrochloride (Antisedan) were from Pfizer
(Sandwich, Kent, UK), buprenorphine (Vetergesic) was from
Alstoe Animal Health (York, UK) and amoxicillin trihydrate
(Amoxycare LA) was from Animalcare Ltd (York, UK). LPS
(Escherichia coli serotype 0127 B8), adenosine, 8-PT were
purchased from Sigma (Dorset, UK) and dissolved in sterile
isotonic saline. CCPA was from Sigma and DPCPX was from
Tocris Cookson (Avonmouth, UK), and both were dissolved
in a vehicle containing 5% propylene glycol and 2% Tween-
80 in saline. Losartan potassium was from Sequoia Research
Products (Oxford, UK), and was dissolved in sterile water.
Bolus injections were given in a volume of 0.1mL and
infusions of adenosine and CCPA were given i.v. at a rate of
0.15mLmin
 1. Drug and molecular target nomenclature
conforms with the British Journal of Pharmacology Guide to
Receptors and Channels (Alexander et al., 2008).
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Cardiovascular responses to LPS administration
Five independent groups of rats were given LPS (1mgkg
 1
i.p.), with subsequent administration of 8-PT (experiment 1),
adenosine (experiment 2), CCPA at 1.5 or 6h (experiments
3a and b) or DPCPX (experiment 4). The changes in
cardiovascular variables in the group of animals that received
no intervention other than LPS up to the 6h time point
(Experiment 3b) are shown in Figure 1. In these animals,
relative to the original baseline (Friedman’s test), there was
tachycardia which was significant from 30min onwards. At
30min there was a rise in BP accompanied by mesenteric
and hindquarters vasoconstriction, but thereafter, BP fell
(Po0.05 at 1.5 and 2h), with renal and hindquarters
vasodilatation. Subsequently (between 2 and 5h), there
was a recovery in BP with mesenteric and hindquarters
vasoconstriction, although the renal vasodilatation per-
sisted. Then, between 5 and 6h, BP fell again, with
vasodilatation in all three vascular beds (Figure 1). Compared
with the corresponding saline group, at 1.5h there was
tachycardia and renal and mesenteric vasodilatations in
LPS-treated rats, and at 6h there was tachycardia and
vasodilatation in all three vascular beds (Po0.05,
Wilcoxon’s test) (Figure 1).
Cardiovascular variables in the five groups of LPS-treated
rats and the corresponding saline controls at 1.5, 6 and 25h
(where recorded), prior to administration of the adenosine
agonist or antagonist are shown in Table 1. In all groups, at
1.5h after saline or LPS administration (that is, prior to
administration of any adenosine agonist/antagonist), the
differences between the saline and LPS groups were qualita-
tively similar, although in some groups the changes were not
significant. Thus, there was tachycardia (significant in all
groups), some increase in renal vascular conductance (sig-
nificant in experiment 3b), a decrease in mesenteric vascular
conductance (significant in experiments 2, 3b and 4) and an
increase in hindquarters vascular conductance (significant in
experiment 1). Similarly, at 6h after saline or LPS adminis-
tration, there was tachycardia (significant in all groups), an
increase in renal vascular conductance (significant in all
groups except those given DPCPX), an increase in mesenteric
vascular conductance in all groups except those
given DPCPX (see Discussion and conclusions) and
an increase in hindquarters vascular conductance
(significant in experiments 1, 2 and 3b). In the two
groups studied at 25h after saline or LPS administration,
heart rate was no longer different, but the LPS-treated
rats had an increase in hindquarters vascular conductance
with a lower BP (significant in experiment 1). Thus, the
experiments designed to explore a role for adenosine were
performed when a hyperdynamic circulation was beginning
to develop (1.5h), was fully developed (6h) and when
cardiovascular variables were returning to near normal
levels (25h).
Experiment 1: cardiovascular effects of 8-PT in normal and
LPS-treated rats
Cardiovascular responses to the non-selective adenosine
receptor antagonist, 8-PT (4mgkg
 1 i.v. bolus) after LPS or
saline treatment are shown in Figure 2. In saline-treated
animals, administration of 8-PT at all three time points
caused significant tachycardia, which was sometimes
accompanied by a rise in BP (Po0.05 at 6 and 25h), a fall
in renal vascular conductance (Po0.05 at 6 and 25h)
and a rise in hindquarters vascular conductance (Po0.05
at 1.5 and 25h).
At 1.5h after LPS treatment, 8-PT caused tachycardia,
hypotension, renal and hindquarters vasodilatation
(Figure 2); the integrated (0–10min) changes in BP
and renal vascular conductance were significantly different
from those seen in the saline-treated rats (Figure 2a). At
6h after LPS treatment, 8-PT caused no tachycardia but
there was hypotension and hindquarters vasodilatation
(Figure 2b); the integrated (0–10min) changes in heart rate,
BP and hindquarters vascular conductance were significantly
different from those seen in the saline-treated rats. The
integrated (0–10min) change in renal vascular conductance
in response to 8-PT was also different in LPS-treated rats at
this juncture, inasmuch as the renal vasoconstrictor
responses seen in the controls were absent. At 25h following
LPS treatment, the integrated (0–10min) responses to 8-PT
were not different between the saline- and LPS-treated
animals (Figure 2c).
Figure 1 Changes in cardiovascular variables over a 6-h period
following administration of LPS (1mgkg
 1 i.p.) or saline (0.5mL i.p.)
in conscious Sprague–Dawley rats (n¼8). Values are mean and vertical
bars represent the s.e. *Po0.05 vs original baseline (Friedman’s
test).
#Po0.05 vs integrated (0–360min) changes between groups
(Wilcoxon’s test).
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and LPS-treated rats
Cardiovascular responses to adenosine (300mgkg
 1min
 1)
are shown in Figure 3. In saline-treated rats, adenosine
caused tachycardia, a fall in BP and increases in vascular
conductance in the renal, mesenteric and hindquarters
vascular beds.
At 1.5h following LPS treatment (Figure 3a), the adeno-
sine-induced tachycardia was abolished and this was accom-
panied by a hypotension that took longer to develop than in
the saline group. There was a tendency for an initial renal
vasoconstriction but there was a small vasodilatation by
the end of the infusion, and robust increases in mesenteric
and hindquarters vascular conductances. The integrated
Table 1 Cardiovascular variables prior to administration of adenosine agonists and antagonists
Experiment 1 Experiment 2 Experiment 3a Experiment 3b Experiment 4
Saline LPS Saline LPS Saline LPS Saline LPS Saline LPS
1.5h
Heart rate (beatsmin
 1)3 4 7 ±7 402±16* 340±10 429±14* 336±6 385±8* 352±74 2 7 ±9* 351±7 415±10*
Mean BP (mmHg) 113±3 104±5 102±21 0 4 ±2 110±2 108±51 0 9 ±91 0 3 ±3* 110±2 116±6
Renal VC (U) 77±10 99±97 5 ±88 7 ±10 94±5 109±77 4 ±89 0 ±9* 91±99 5 ±5
Mesenteric VC (U) 69±85 9 ±57 7 ±94 9 ±7* 66±55 0 ±97 2 ±76 2 ±8* 64±43 5 ±4*
Hindquarters VC (U) 44±46 2 ±7* 54±35 6 ±54 5 ±55 2 ±64 5 ±64 7 ±94 7 ±25 3 ±4
6h
Heart rate (beatsmin
 1)3 5 3 ±12 445±12* 343±10 429±14* 337±8 399±14* 360±11 416±6* 340±7 399±8*
Mean BP (mmHg) 112±39 2 ±6* 102±29 2 ±3 107±1 102±31 1 1 ±39 9 ±3 111±2 114±7
Renal VC (U) 78±10 134±15* 74±71 0 9 ±16* 89±3 112±6* 75±89 8 ±11* 96±9 107±14
Mesenteric VC (U) 57±6 128±10* 83±91 0 8 ±14* 62±28 4 ±9* 70±81 0 6 ±1* 59±55 7 ±9
Hindquarters VC (U) 43±46 7 ±6* 52±36 7 ±3* 42±44 8 ±64 2 ±55 3 ±5* 42±24 5 ±3
25h
Heart rate (beatsmin
 1)3 5 1 ±7 383±21 356±10 352±11
Mean BP (mmHg) 114±3 101±4* 107±11 0 0 ±2
Renal VC (U) 79±78 7 ±57 0 ±98 1 ±14
Mesenteric VC (U) 68±78 3 ±76 8 ±11 76±9
Hindquarters VC (U) 43±46 1 ±6* 45±36 3 ±4*
Abbreviations: LPS, lipopolysaccharide; U, units; VS, vascular conductance.
Values are mean±s.e. Units for vascular conductance (VC) are kHzmmHg
 1 10
3. n¼8–9 per group. *Po0.05 vs corresponding saline group.
Figure 2 Cardiovascular responses to 8-PT (4mgkg
 1 i.v.) at (a) 1.5h, (b) 6h and (c) 25h following administration of saline (0.5mL i.p.) or
LPS (1mgkg
 1 i.p.) in conscious Sprague–Dawley rats (n¼9 in each group). Values are mean and vertical bars represent the s.e. *Po0.05 vs
original baseline (Friedman’s test).
#Po0.05 vs integrated (0–10min) changes between groups (Mann–Whitney test).
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tance in response to adenosine at 1.5h were significantly
(Po0.05) less in the LPS group than in the control group, but
the integrated changes in mesenteric and hindquarters
vascular conductance were not significantly different in the
two groups. At 6h after LPS (Figure 3b), adenosine caused a
slight tachycardia although the integrated (0–3min) change
was still less than the control. The accompanying hypo-
tension was again slower in onset but the integrated change
was not different from the control. At this juncture, the renal
vasodilatation was still significantly different from control,
the mesenteric vasodilatation was not different from control,
but the hindquarters vasodilator response to adenosine was
lost (Figure 3b). By 25h after the administration of LPS, the
cardiovascular responses to adenosine were not different
between the saline- and LPS-treated groups (Figure 3c).
Experiment 3: cardiovascular responses to CCPA
Separate groups of animals were given CCPA at 1.5 or 6h as we
(L Jolly, unpublished observations) and others (Casati et al.,
1994; Saura et al., 1998) found evidence of desensitization
following repeated administration of this agonist.
In saline-treated animals, CCPA caused bradycardia,
hypotension, mesenteric and renal vasoconstriction and
hindquarters vasodilatation (Figure 4). For no obvious
reason, although the changes were qualitatively similar at
1.5 and 6h, the magnitude of change in BP, heart rate and
renal and mesenteric vascular conductances in response to
CCPA were smaller at 6h than at 1.5h (Po0.05 for integrated
0–3min responses in both saline and LPS groups), despite the
use of naive animals at the two time points (Figure 4).
At 1.5h after LPS administration, the integrated (0–3min)
bradycardic response to CCPA was greater, but the hypo-
tension and mesenteric vasoconstriction were less than in
the saline-treated animals at that time (Figure 4a). At 6h
after LPS treatment, the integrated bradycardia was still
greater, but the renal and mesenteric vasoconstrictions were
also greater than those in the corresponding saline control
(Figure 4b). The hindquarters vasodilator response to
CCPA did not differ between saline- and LPS-treated rats
at any stage.
Experiment 4: cardiovascular effects of 8-DPCPX in normal and
LPS-treated rats
Haemodynamic responses to DPCPX treatment in saline-
and LPS-treated animals are shown in Figure 5. In the saline-
treated group, responses were quite variable but DPCPX
caused a small (significant at 1.5h only) rise in BP with
mesenteric and hindquarters vasoconstriction (significant at
both time points).
In the LPS-treated group, at 1.5h, the integrated (0–
10min) mesenteric and hindquarters vasoconstrictor re-
sponses to DPCPX were not different from the saline-treated
group but there was renal vasodilatation (not seen in the
control group) and the pressor response was lost (Figure 5a).
At 6h after LPS treatment, there were no significant changes
in any haemodynamic variable following administration of
DPCPX (Figure 5b), and the integrated (0–10min) changes in
BP and renal and hindquarters vascular conductances were
significantly less than in the saline-treated rats.
Experiment 5: cardiovascular effects of DPCPX following
pretreatment with losartan
In losartan-treated rats, 1.5 and 6h after saline, resting
cardiovascular variables were heart rate 358±6 and 368±15
beatsmin
 1, BP 100±3 and 95±2mmHg, renal vascular
conductance 109±10 and 110±10 (kHzmmHg
 1)10
3,
Figure 3 Cardiovascular responses to 3-min infusions of adenosine (300mgkg
 1min
 1 i.v.) at (a) 1.5h, (b) 6h and (c) 25h following
administration of saline (0.5mL i.p.) or LPS (1mgkg
 1 i.p.) in conscious Sprague–Dawley rats (n¼9). Values are mean and vertical bars
represent the s.e. *Po0.05 vs original baseline (Friedman’s test).
#Po0.05 vs integrated (0–3min) changes between groups (Wilcoxon’s test).
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(kHzmmHg
 1)10
3 and hindquarters vascular conductance
49±5 and 53±4 (kHzmmHg
 1)10
3.
In the presence of losartan, DPCPX had no significant
effect on BP or heart rate, but caused a fall in mesenteric
vascular conductance (Po0.05 at 1.5 and 6h), and a fall in
hindquarters vascular conductance (Po0.05 at 1.5h only).
At 1.5h, the integrated (0–10min) fall in mesenteric vascular
conductance in response to DPCPX was significantly smaller
following losartan ( 76±20%) than in the control condition
( 136±24%), and at both times, the DPCPX-induced fall in
hindquarters vascular conductance was smaller after losartan
(at 1.5h  67±16%, at 6h  31±18%) than in the control
condition ( 97±20,  100±15% respectively), although the
difference was only significant at 6h.
Discussion and conclusions
Previous reports have shown a vasodilator role for adenosine
24h after the onset of sepsis induced by injection of caecal
slurry (Motew et al., 1998; Sam et al., 2000). To extend these
observations, the present studies were designed to investi-
gate the role of adenosine in the early cardiovascular changes
seen in a rat model of endotoxaemia that is characterized
by regionally selective vasodilatation, the pattern of which
varies across time. The endotoxaemic model used here
(1mgkg
 1 LPS given as a bolus i.p.) has not been used by
our group previously and, although at the low end of the
range of LPS doses used by others (from 0.5mgkg
 1
(Nishiyama et al., 1999) to 100mgkg
 1 (Dackor and Caron,
2007)), we showed that it caused marked renal vasodilatation
that was early in onset, mesenteric vasodilatation that was
slow to develop and preceded by vasoconstriction, and
hindquarters vasodilatation that was biphasic. The accom-
panying changes in BP were very modest, but there was
pronounced tachycardia. This haemodynamic profile is
consistent with the hyperdynamic circulation that is seen
in the early stages of clinical sepsis.
In saline-treated animals, the effects of 8-PT were con-
sistent with endogenous adenosine causing bradycardia
(Evoniuk et al., 1987) and vasodilatation in the hindquarters.
The magnitude of the responses to 8-PT varied across time
(Figure 2), possibly due to variations in the levels of
endogenous adenosine, which may reflect changes in the
energy status of animals following surgery. In the LPS-treated
animals, there were some notable changes in responses to
8-PT which, in this condition, caused hypotension asso-
ciated with renal vasodilatation at 1.5h, and hindquarters
vasodilatation at 6h. By 25h after LPS administration,
responses to 8-PT had returned to normal. As Motew et al.
(1998) reported a vasoconstrictor effect of 8-PT in sepsis,
our results showing 8-PT-induced vasodilatation were
unexpected, but would be consistent with upregulation of
endogenous adenosine-induced vasoconstriction and/or
downregulation of a endogenous adenosine-induced vaso-
Figure 4 Cardiovascular responses to 3-min infusions of CCPA (1.4mgkg
 1min
 1 i.v.) at (a) 1.5h and (b) 6h following administration of
saline (0.5mL i.p.) or LPS (1mgkg
 1 i.p.) in conscious Sprague–Dawley rats (n¼8). Values are mean and vertical bars represent the s.e.
*Po0.05 vs original baseline (Friedman’s test).
#Po0.05 vs integrated (0–3min) changes between groups (Wilcoxon’s test).
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the widespread vasodilator response to exogenous adenosine
in normal animals was lost in the renal vascular bed 1.5h
after LPS administration and was absent in the hindquarters
vascular bed 6h after LPS administration. Others have
described A1-receptor-mediated constriction of renal afferent
arterioles in normal animals (Tagawa and Vander, 1970;
Webb et al., 1990; Tang et al., 1999), and here we also found
that, in the control animals, adenosine caused some fall in
renal vascular conductance prior to the development of the
vasodilatation. The findings of attenuated vasodilator
responses to adenosine in the renal vascular bed at 1.5h,
and in the hindquarters at 6h following LPS administration
are internally consistent with the effects of 8-PT (see above),
and suggest either an LPS-induced enhancement of
A1-receptor-mediated vasoconstriction or an impairment of
A2-receptor-mediated vasodilatation in these regions at these
times. Interestingly, the adenosine-induced tachycardia
observed in normal animals was also substantially reduced
in the LPS-treated animals. As there was a resting tachycardia
following LPS treatment (Table 1), one theoretical
explanation for the lack of tachycardic response to
adenosine is that the resting heart rate was already high so
could not increase further. However, we feel this is unlikely
as the LPS-treated rats showed tachycardic responses to 8-PT
(experiment 1), and from our previous experiences, the level
of heart rate in the LPS-treated rats in this experiment (B420
beatsmin
 1) was not maximal for a conscious rat.
The heart rate response to adenosine administration in
normal animals is complex, as A1 receptor activation causes
bradycardia (Hintze et al., 1985; Evoniuk et al., 1987;
Fredholm et al., 1987), whereas A2 receptor activation causes
tachycardia, partly as a reflex response to the hypotensive
effects of A2-receptor-mediated vasodilatation (Ohnishi
et al., 1986), but also possibly due to a direct effect of A2
receptor activation in the heart (Lappe et al., 1992) and/or
via an effect in the CNS (Schindler et al., 2005). Because
adenosine caused a similar fall in BP in control and
LPS-treated rats, the lack of tachycardia in the latter could
indicate some impairment of the baroreflex, and/or
reduction of the direct effects of A2 receptors on the heart
(Lappe et al., 1992) and/or an enhancement of the direct
action of A1 receptors on the heart.
As one interpretation of the findings from the experiments
using 8-PT and adenosine was that there were enhanced A1-
receptor-mediated responses in LPS-treated rats (see above),
further experiments were performed using the selective A1
receptor agonist, CCPA, and the A1 receptor antagonist,
DPCPX. In control animals, CCPA caused bradycardia,
hypotension, renal and mesenteric vasoconstriction and
hindquarters vasodilatation. These findings are consistent
with those reported by Webb et al. (1990) in spontaneously
hypertensive rats, showing that A1-receptor-mediated vasocons-
triction (Tagawa and Vander, 1970; Barrett and Droppleman,
1993; Hansen et al., 2005) is not restricted to the renal
vasculature, and that the hypotension may largely be due to
Figure 5 Cardiovascular responses to DPCPX (0.1mgkg
 1 i.v.) at (a) 1.5h and (b) 6h following administration of saline (0.5mL i.p.) or LPS
(1mgkg
 1 i.p.) in conscious Sprague–Dawley rats (n¼8). Values are mean and vertical bars represent the s.e. *Po0.05 vs original baseline
(Friedman’s test).
#Po0.05 vs integrated (0–10min) changes between groups (Wilcoxon’s test).
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hindquarters vasodilatation. The hindquarters vasodilator
response to CCPA is also consistent with reports by others
showing A1-receptor-mediated vasodilatation in skeletal
muscle (Marshall et al., 1993; Ray et al., 2002; Ray and
Marshall, 2006). In the light of experiments with 8-PT and
adenosine (see above), we hypothesized that there would be
enhanced CCPA-induced renal vasoconstriction 1.5h after
LPS treatment, enhanced hindquarters vasoconstriction (or
diminished vasodilatation) 6h after LPS, and enhanced
bradycardia at both time points. Our data did indeed show
enhanced CCPA-induced bradycardia in the LPS-treated
group, which is consistent with an upregulation of
A1-receptor-mediated negative chronotropic actions. How-
ever, there was no enhancement of the CCPA-induced renal
vasoconstriction at 1.5h and no change in the hindquarters
vascular response at 6h after LPS. Others have shown that
endogenous NO may blunt the renal vasoconstrictor
response to CCPA (Barrett and Droppleman, 1993). Thus, it
is possible that the apparently normal renal vasoconstrictor
response to CCPA in LPS-treated animals was due to
enhanced production of NO offsetting augmented
A1-receptor-mediated renal vasoconstriction. Alternatively,
it may be that there was no upregulation of A1-receptor-
mediated renal vasoconstriction following LPS treatment,
and our results with 8-PT and adenosine were due to a
downregulation of A2-receptor-mediated renal vasodilata-
tion. Similarly, at 6h after LPS administration, there was no
evidence for upregulation of A1-receptor-mediated vaso-
constriction in the hindquarters, and hence the results
with adenosine and 8-PT in this vascular bed could also
be explained by downregulation of A2-receptor-mediated
responses. Interestingly, at 1.5h after LPS, the mesenteric
vasoconstrictor response to CCPA was diminished at a
time when the bradycardia was enhanced and yet the
hypotension was unaffected. This must indicate differential
changes in cardiac output in response to CCPA in control vs
LPS-treated rats at this time, with a larger reduction in
cardiac output in the former, possibly due to the larger
increase in afterload secondary to the greater mesenteric
vasoconstriction.
In the final set of experiments, DPCPX was used to study
endogenous A1 receptor activation in normal and endotox-
aemic rats. In control animals, DPCPX caused a modest
increase in BP, together with mesenteric and hindquarters
vasoconstriction, but no significant effect on renal vascular
conductance. As the mesenteric and hindquarters vasocon-
strictor effects of DPCPX were reduced by losartan, it is likely
that these responses were, at least in part, secondary to the
blockade of A1-receptor-mediated inhibition of renin release
(Tagawa and Vander, 1970; Jackson, 1991). The lack of
response to DPCPX in the renal vasculature indicates that
levels of endogenous adenosine were insufficient to activate
renal A1 receptors in normal animals. This is in line with a
study by Kellett et al. (1989) who found that DPCPX had
no effect on renal blood flow under normal conditions,
and suggests that the observed responses to 8-PT in control
animals may have been mediated by inhibition of A2
receptors. Interestingly, in LPS-treated rats, DPCPX caused
renal vasodilatation at 1.5h, consistent with the results from
the experiments with 8-PT, and suggesting that endogenous
adenosine was acting at renal A1 receptors to cause
vasoconstriction. Because the vascular responsiveness to
the A1 receptor agonist, CCPA, was not enhanced 1.5h
following LPS treatment, it is likely that the responses to
DPCPX reflect inhibition of enhanced adenosine produc-
tion. However, unlike 8-PT, DPCPX did not cause vasodilata-
tion in the hindquarters vascular bed at 6h after LPS, which
suggests that the results with 8-PT and adenosine may be
explained by reduced A2-receptor-mediated vasodilatation in
that vascular bed at that time.
Interestingly, rats given DPCPX at 1.5h did not develop
mesenteric vasodilatation across the 2- to 6-h period
following LPS treatment (Table 1), suggesting that the earlier
A1 receptor antagonism blunted the development of the
hyperdynamic circulation. One explanation for this attenu-
ated baseline vasodilatation in the DPCPX-treated group is
that there was increased activation of the renin–angiotensin
system, consequent upon removal of the normal A1-
receptor-mediated inhibition of this system (Weihprecht
et al., 1990; Lappe et al., 1992).
Some of the effects of DPCPX are difficult to explain. All
the foregoing experiments had indicated upregulation of the
A1-receptor-mediated, negative chronotropic effects of ade-
nosine in endotoxaemia and, therefore, we predicted that
there would be a tachycardic response to DPCPX, but this
was not the case. Hence, the effects of 8-PT may have been
due to inhibition of A2-receptor-mediated cardiac effects,
and the findings of enhanced CCPA-induced bradycardia,
but no DPCPX-induced tachycardia, could indicate increased
sensitivity of A1 receptors in the heart, but insufficient
endogenous adenosine to activate the receptors.
Adenosine receptors are widely distributed throughout
the CNS and A2a receptors are implicated in the control
of baroreceptor-mediated reflexes (Thomas et al., 2000).
Furthermore, Schindler et al. (2005) showed that, in
conscious rats, although the hypotensive and bradycardic
effects of i.p. A1 receptor agonist administration were due to
peripheral A1 receptor activation, A2a-receptor-mediated
hypotension was due to activation of peripheral receptors,
but the tachycardia was, at least in part, due to activation of
centrally located receptors (Schindler et al., 2005). Therefore,
it is possible that some of the results presented here reflect
activation of central as well as peripheral adenosine
receptors. Indeed, as the integrity of the blood–brain barrier
is compromised during sepsis, an increased involvement of
centrally-located adenosine receptors following LPS treat-
ment in our studies is feasible.
In conclusion, the present studies show that the regional
haemodynamic effects of adenosine receptor activation and
antagonism change in a regionally distinct manner, across
time following LPS treatment in conscious rats. Our results
show that upregulation of A1-receptor-mediated effects
could only partly explain the changed cardiovascular
response to adenosine at 1.5 and 6h after LPS treatment,
and we therefore suggest that downregulation of A2-
receptor-mediated action may also have been involved.
Thus, the cardiovascular effects of adenosine during LPS-
induced endotoxaemia appear to vary according to the
receptor activated, the vascular bed and the time elapsed
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compounds are not currently used in the treatment of sepsis,
their potential usefulness is under discussion (for reviews, see
Sands and Palmer, 2005; Skrabanja et al., 2005). The present
findings indicate that any therapeutic potential of adenosine
agonists and antagonists needs to be considered in the
context of the possibility of their exerting different effects in
different vascular beds, with these putative actions varying
as a function of time after the onset of sepsis.
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